Bluejay Diagnostics Files 8-K: Officer & Director Changes

Ticker: BJDX · Form: 8-K · Filed: 2025-05-28T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes

Related Tickers: BJDX

TL;DR

Bluejay Diagnostics (BJDX) filed an 8-K for director/officer changes and comp arrangements. Details TBD.

AI Summary

Bluejay Diagnostics, Inc. filed an 8-K on May 28, 2025, reporting changes in its board of directors and certain officers, along with updates on compensatory arrangements. The filing also includes financial statements and exhibits, though specific details on dollar amounts or new appointments were not immediately available in the provided text.

Why It Matters

Changes in a company's leadership and compensation structures can signal shifts in strategy or financial health, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Filings related to executive and board changes can indicate internal shifts that may affect company direction and stability.

Key Players & Entities

FAQ

What specific changes were made regarding directors or officers?

The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific names and roles are not detailed in the provided text.

Are there any new compensatory arrangements disclosed?

The filing mentions 'Compensatory Arrangements of Certain Officers', but the specifics of these arrangements are not provided in the excerpt.

What is the exact date of the earliest event reported in this 8-K?

The date of the earliest event reported is May 28, 2025.

What is Bluejay Diagnostics' principal executive office address?

The principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

What is the SIC code for Bluejay Diagnostics, Inc.?

The Standard Industrial Classification (SIC) code for Bluejay Diagnostics, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

From the Filing

0001213900-25-048343.txt : 20250528 0001213900-25-048343.hdr.sgml : 20250528 20250528171849 ACCESSION NUMBER: 0001213900-25-048343 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250528 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250528 DATE AS OF CHANGE: 20250528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bluejay Diagnostics, Inc. CENTRAL INDEX KEY: 0001704287 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 473552922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41031 FILM NUMBER: 25996568 BUSINESS ADDRESS: STREET 1: 360 MASSACHUSETTS AVENUE, SUITE 203 CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: (978) 631-0152 MAIL ADDRESS: STREET 1: 360 MASSACHUSETTS AVENUE, SUITE 203 CITY: ACTON STATE: MA ZIP: 01720 8-K 1 ea0243732-8k_bluejay.htm CURRENT REPORT false 0001704287 0001704287 2025-05-28 2025-05-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): May 28, 2025         BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter)       delaware   001-41031   47-3552922 (State or Other Jurisdiction of Incorporation or Organization)   (Commission File No.)   (I.R.S. Employer Identification No.)   360 Massachusetts Avenue , Suite 203 Acton , MA 01720 (Address of principal executive offices and zip code)   ( 844 ) 327-7078 (Registrant’s telephone number, including area code)     (Former name or former address, if changed from last report)       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol (s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   BJDX   The Nasdaq Capital Market               Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   As previously reported by Bluejay Diagnostics, Inc. (the “Company”) in its Q

View on Read The Filing